EFFICACY AND COST OF GRANISETRON VERSUS ONDANSETRON IN THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING AMONG CANCER PATIENTS AT KENYATTA NATIONAL HOSPITAL
EFFICACY AND COST OF GRANISETRON VERSUS ONDANSETRON IN THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING AMONG CANCER PATIENTS AT KENYATTA NATIONAL HOSPITAL
复制标题
DOI：
10.13040/ijpsr.0975-8232.9(4).1644-49
复制
发表时间：
2018-04-01
期刊：
影响因子：
--
通讯作者：
Maranga, I. S. O.
中科院分区：
文献类型：
--
作者：
Innocent, Muhire;Karimi, P. N.;Maranga, I. S. O.
昂丹司琼和格拉司琼之间的成本差异和疗效相似性已在许多临床研究中报道，并促使本研究确定这种差异是否像肯雅塔国立医院一样重要。34名计划开始其连续三周周期的基于顺铂的化疗方案的成年癌症患者被招募到双盲随机交叉研究中，以在第一天静脉内接受昂丹司琼12 mg或格拉司琼3 mg各联合地塞米松8 mg，并从第2天至第4天继续其各自的口服组合。在5天的止吐治疗期间，每天记录恶心和呕吐的频率。使用封闭式问卷收集数据，并使用STATA第13版软件进行统计分析。使用Fisher精确检验检查统计学显著性，并在p值小于0.05时进行考虑。女性占70.6%，50-70岁占47.1%，平均年龄为53.5（+/- 11.9）岁，宫颈癌是主要癌症。在约80%接受任一治疗的患者中观察到急性和迟发性呕吐/恶心的完全预防。直接成本与格拉司琼为基础的止吐治疗方案相比，昂丹司琼在约10：1的比例较高。昂丹司琼和格拉司琼分别与地塞米松联合使用具有相似的疗效;每种药物的选择取决于成本。恩丹西酮应优于格拉司琼，延迟化疗引起的恶心和呕吐需要进一步研究。
Differences in cost and similarities in the efficacy between ondansetron and granisetron have been reported in many clinical studies and prompted this study to determine whether such differences are important as Kenyatta National Hospital. Thirty-four adult cancer patients scheduled to start their consecutive three weekly cycles of cisplatin-based chemotherapy regimens, were recruited into a double-blind randomized crossover study to receive ondansetron 12 mg or granisetron 3 mg each combined with dexamethasone 8 mg as intravenous on the first day and continued on their respective oral combinations from day 2 to 4. The frequency of nausea and vomiting were recorded daily during 5 days of antiemetic treatment. Data were collected using a close ended questionnaire and statistical analysis was performed using STATA version 13 software. Statistical significance was checked using Fisher's exact test and was considered when p value was less than 0.05. Female predominance was 70.6%, while dominant age was 50-70 years at 47.1% with a mean age of 53.5 (+/- 11.9) years and cervical cancer was leading cancer. Complete prevention of acute and delayed vomiting/nausea was observed in about 80 % of patients receiving either of the treatments. Direct cost with granisetron based antiemetic treatment regimen was higher compared with the one with ondansetron at a ratio of approximately 10:1. Ondansetron and granisetron each combined with dexamethasone have similar efficacy; the choice of each can depend on the cost. Ondansetron should be preferred to granisetron and further research for delayed chemotherapy induced nausea and vomiting requires to be done.